{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:42:39Z","timestamp":1790700159786,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2019-05429"],"award-info":[{"award-number":["2019-05429"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011963","name":"European Academy of Neurology","doi-asserted-by":"publisher","award":["2021 Research Fellowship Grant"],"award-info":[{"award-number":["2021 Research Fellowship Grant"]}],"id":[{"id":"10.13039\/501100011963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune neuromuscular disease characterized by fatigable skeletal muscle weakness with a fluctuating unpredictable course. One main concern in MG is the lack of objective biomarkers to guide individualized treatment decisions. Specific circulating serum microRNAs (miRNAs) miR-30e-5p, miR-150-5p and miR-21-5p levels have been shown to correlate with clinical course in specific MG patient subgroups. The aim of our study was to better characterize these miRNAs, regardless of the MG subgroup, at an early stage from diagnosis and determine their sensitivity and specificity for MG diagnosis, as well as their predictive power for disease relapse. Serum levels of these miRNAs in 27 newly diagnosed MG patients were compared with 245 healthy individuals and 20 patients with non-MG neuroimmune diseases. Levels of miR-30e-5p and miR-150-5p significantly differed between MG patients and healthy controls; however, no difference was seen compared with patients affected by other neuroimmune diseases. High levels of miR-30e-5p predicted MG relapse (p = 0.049) with a hazard ratio of 2.81. In summary, miR-150-5p is highly sensitive but has low specificity for MG, while miR-30e-5p has the greatest potential as a predictive biomarker for the disease course in MG, regardless of subgroup.<\/jats:p>","DOI":"10.3390\/cells11040740","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:14:46Z","timestamp":1645431286000},"page":"740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p"],"prefix":"10.3390","volume":"11","author":[{"given":"Francesca","family":"Beretta","sequence":"first","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, 75185 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, 75185 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-Specific Kinase Myasthenia Gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime Course of Myasthenia Gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia Gravis: A Comprehensive Review of Immune Dysregulation and Etiological Mechanisms","volume":"52","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in Myasthenia Gravis in the Era of Biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2020.00213","article-title":"Circulating MiRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine","volume":"11","author":"Sabre","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.21713","article-title":"History of Outcome Measures for Myasthenia Gravis","volume":"42","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"596382","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2012.06787.x","article-title":"Biomarker Development for Myasthenia Gravis","volume":"1275","author":"Kaminski","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular MiRNAs: From Biomarkers to Mediators of Physiology and Disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating MicroRNA MiR-21-5p, MiR-150-5p and MiR-30e-5p Correlate with Clinical Status in Late Onset Myasthenia Gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy Lowers the Myasthenia Gravis Biomarker MiR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in Myasthenia Gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease Specific Signature of Circulating MiR-150-5p and MiR-21-5p in Myasthenia Gravis Patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5777383","DOI":"10.1016\/j.jneuroim.2020.577383","article-title":"Low-Dose Rituximab Lowers Serum Exosomal MiR-150-5p in AChR-Positive Refractory Myasthenia Gravis Patients","volume":"348","author":"Zhong","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"MiR-30e-5p as Predictor of Generalization in Ocular Myasthenia Gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1261\/rna.059063.116","article-title":"Practical Data Handling Pipeline Improves Performance of qPCR-Based Circulating miRNA Measurements","volume":"23","author":"Ruijter","year":"2017","journal-title":"RNA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2021.11897","article-title":"Comparison and Optimisation of MicroRNA Extraction from the Plasma of Healthy Pregnant Women","volume":"23","author":"Parker","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","article-title":"Assessing Sample and MiRNA Profile Quality in Serum and Plasma or Other Biofluids","volume":"59","author":"Blondal","year":"2013","journal-title":"Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing Real-Time PCR Data by the Comparative CT Method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12367","article-title":"Immuno-MiRs: Critical Regulators of T-Cell Development, Function and Ageing","volume":"144","author":"Kroesen","year":"2015","journal-title":"Immunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and Consequences of MiR-150-5p Dysregulation in Myasthenia Gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.21037\/atm-21-4151","article-title":"A Novel Immune-Related ceRNA Network That Predicts Prognosis and Immunotherapy Response in Lung Adenocarcinoma","volume":"9","author":"Gong","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"616372","DOI":"10.3389\/fonc.2021.616372","article-title":"Identification and Confirmation of the MiR-30 Family as a Potential Central Player in Tobacco-Related Head and Neck Squamous Cell Carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2020.00151","article-title":"Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating MicroRNAs","volume":"11","author":"Fiorillo","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Keller, A., Leidinger, P., Lange, J., Borries, A., Schroers, H., Scheffler, M., Lenhof, H.P., Ruprecht, K., and Meese, E. (2009). Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007440"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.23880","article-title":"Circulating MicroRNAs as Biomarkers for Disease Staging in Multiple Sclerosis","volume":"73","author":"Gandhi","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tan.12874","article-title":"Circulating Hsa-MiR-30e-5p, Hsa-MiR-92a-3p, and Hsa-MiR-223-3p May Be Novel Biomarkers in Systemic Lupus Erythematosus","volume":"88","author":"Kim","year":"2016","journal-title":"HLA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"668760","DOI":"10.3389\/fimmu.2021.668760","article-title":"Resolvin D1 Improves the Treg\/Th17 Imbalance in Systemic Lupus Erythematosus Through MiR-30e-5p","volume":"12","author":"Cheng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.30131","article-title":"MicroRNA Expression Profiles as Biomarkers of Minor Salivary Gland Inflammation and Dysfunction in Sj\u00f6gren\u2019s Syndrome","volume":"63","author":"Alevizos","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lopes, A.P., Hillen, M.R., Chouri, E., Blokland, S.L.M., Bekker, C.P.J., Kruize, A.A., Rossato, M., van Roon, J.A.G., and Radstake, T.R.D.J. (2018). Circulating Small Non-Coding RNAs Reflect IFN Status and B Cell Hyperactivity in Patients with Primary Sj\u00f6gren\u2019s Syndrome. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193157"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chen, J.Q., Papp, G., P\u00f3liska, S., Szab\u00f3, K., Tarr, T., B\u00e1lint, B.L., Szodoray, P., and Zeher, M. (2017). MicroRNA Expression Profiles Identify Disease-Specific Alterations in Systemic Lupus Erythematosus and Primary Sj\u00f6gren\u2019s Syndrome. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174585"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1212\/NXI.0000000000000219","article-title":"Circulating MiR-150 in CSF Is a Novel Candidate Biomarker for Multiple Sclerosis","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fnins.2018.00465","article-title":"Silencing MiR-150 Ameliorates Experimental Autoimmune Encephalomyelitis","volume":"12","author":"Hu","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pan.2020.02.012","article-title":"Extracellular Vesicles MicroRNA Analysis in Type 1 Autoimmune Pancreatitis: Increased Expression of MicroRNA-21","volume":"20","author":"Nakamaru","year":"2020","journal-title":"Pancreatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3899\/jrheum.190602","article-title":"Serum Microrna Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis","volume":"47","author":"Wade","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jneuroim.2018.01.005","article-title":"Immune-Related MiRNA Expression Patterns in Peripheral Blood Mononuclear Cells Differ in Multiple Sclerosis Relapse and Remission","volume":"317","author":"Baulina","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108071","DOI":"10.1016\/j.intimp.2021.108071","article-title":"Prediction and Analysis of MicroRNAs Involved in COVID-19 Inflammatory Processes Associated with the NF-KB and JAK\/STAT Signaling Pathways","volume":"100","author":"Arab","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.msard.2017.05.009","article-title":"Epstein\u2013Barr Virus and Multiple Sclerosis: Updating Pender\u2019s Hypothesis","volume":"16","author":"Laurence","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","article-title":"Chronic Inflammatory Demyelinating Polyneuropathy as an Autoimmune Disease","volume":"102","author":"Vatti","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia Gravis: Recommendations for Clinical Research Standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/sim.4780010204","article-title":"Tables Of The Number Of Patients Required In Clinical Trials Using The Logrank Test","volume":"1","author":"Freedman","year":"1982","journal-title":"Stat. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:23:32Z","timestamp":1760135012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11040740"],"URL":"https:\/\/doi.org\/10.3390\/cells11040740","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}